Peptide education
GHK-Cu
Copper tripeptide-1 · Glycyl-L-histidyl-L-lysine copper
GHK-Cu is the copper complex of the small human tripeptide glycyl-L-histidyl-L-lysine. People usually hear about it as copper tripeptide-1 in skin serums, post-procedure skin care, wound-healing research, hair-product marketing, and injectable peptide discussion. The strongest human data here are for topical skin and wound uses, not systemic repair, anti-aging, or injectable wellness.
GHK-Cu has real skin-biology evidence and limited human topical data, but its clearest claims stay close to skin, wound, and formulation context. The studies do not prove injectable repair, systemic anti-aging, hair regrowth, or that GHK-Cu blends work better than topical GHK-Cu alone. A topical cosmetic or wound product should be judged differently from a hair product, injectable vial, or blend because each carries different evidence and quality issues.
Overview
Quick answer
GHK-Cu changes meaning with the product in front of you. A topical cosmetic serum, a post-laser skin-care product, a diabetic-ulcer topical treatment, a compounded preparation, and a gray-market injectable vial raise different evidence, safety, sterility, copper-exposure, and regulatory questions.
What is it?
GHK is a naturally occurring glycyl-L-histidyl-L-lysine tripeptide that binds copper. GHK-Cu refers to the copper complex, often called copper tripeptide-1 in cosmetic and dermatology-adjacent products.
What do people use it for?
The main uses and claims are skin appearance, fine lines, skin texture, post-procedure recovery, wound-healing research, hair and scalp products, and broader peptide-clinic talk about repair or recovery. Topical skin and wound products have the most relevant human data. Hair products and injectable vials rely on different, much thinner evidence. Human evidence is much stronger for topical skin contexts than for injectable or systemic use.
What route, amount, and schedule details appear in the sources?
The clearest documented schedule is topical: a split-face wrinkle study used a GHK-Cu nano-carrier serum twice daily for 8 weeks. Older topical skin and wound studies describe creams, post-laser products, dermal delivery, or ulcer treatment, but they leave no universal milligram amount, frequency, or cycle. Injectable schedules show up in gray-market discussion, but they are not supported by the topical human evidence.
Why do route and product type matter?
Topical GHK-Cu, hair-product claims, wound research, cosmetic labeling, and injectable peptide-market claims involve different evidence. The biggest overstatements apply topical skin data to a different product, route, or goal.
Reported practice
Commonly reported protocol
Injectable community protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
The clearest human evidence is topical: an 8-week split-face wrinkle study, older topical wound and post-laser contexts, and dermal-delivery work that explains why formulation matters.
FDA flags injectable GHK-Cu in its bulk-substance safety-risk materials. The cited human sources do not provide injectable efficacy, systemic safety, or wellness-use evidence.
Hair and scalp claims are part of the market around copper peptides, but the GHK-Cu materials listed here do not verify a standalone hair-regrowth claim, dose, product format, or duration.
FDA cosmetic guidance matters because a skin-appearance product and a disease-treatment or structure-changing claim can fall into different regulatory categories.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| GHK-Cu improves wrinkles or skin appearance. | A randomized split-face study in women used a topical GHK-Cu nano-carrier serum twice daily for 8 weeks and reported reductions in wrinkle volume and depth versus comparator or vehicle. Older cosmetic reports are often discussed around copper peptides, but the clearest human support here comes from topical skin sources. | GHK-Cu is tied to copper binding, dermal formulation, collagen and elastin biology, and skin-delivery questions. Those mechanisms fit a topical skin claim better than a systemic wellness claim. | Cosmetic products commonly use copper tripeptide-1 language for fine lines, texture, firmness, and post-procedure skin support. That market language is product positioning unless it names the actual study, route, and formulation. | The evidence supports a modest topical skin-appearance claim. Skin-aging reversal and injectable use need stronger route-specific evidence. |
| GHK-Cu helps wounds heal. | Human topical material includes diabetic-ulcer context and a post-CO2-laser resurfacing study. That supports wound and post-procedure discussion, but it does not justify a broad wound-healing treatment claim for every topical product or any injectable product. | Copper-binding and skin-remodeling biology help explain why the molecule has been studied in wound and skin contexts. | Clinics and peptide-market discussions often stretch wound language into general repair, tendon, joint, or recovery claims. Those uses sit outside the listed GHK-Cu topical evidence. | The support is narrow: topical wound and post-procedure use can be discussed, but broad injectable repair claims are not supported by the cited evidence. |
| GHK-Cu helps after laser resurfacing or cosmetic procedures. | The post-CO2-laser study was mixed: several objective measures failed to improve significantly, even though patient satisfaction was higher. | Post-procedure skin is a logical place to test topical repair and remodeling products, but a plausible rationale does not override mixed clinical findings. | Post-procedure skin-care routines often include copper-peptide products. That can reflect demand and tolerability expectations rather than measured faster healing. | The post-laser evidence is mixed and specific to topical aftercare; it does not prove that GHK-Cu reliably speeds recovery. |
| GHK-Cu grows hair. | The listed GHK-Cu materials stop short of standalone hair-regrowth efficacy, a controlled scalp regimen, or a reliable duration for hair outcomes. | Copper-peptide and skin-remodeling biology can make hair and scalp interest understandable, but skin formulation data are not the same as a hair-growth trial. | Hair and scalp products commonly attach copper-peptide language to density, shedding, growth support, or post-procedure scalp care. Those claims need product-specific evidence before they become more than market discussion. | Hair is a common market use case, but the listed sources do not make the case for standalone GHK-Cu hair regrowth. |
| Injectable GHK-Cu is a systemic repair or anti-aging peptide. | The cited human evidence is topical and formulation-specific. It leaves injectable GHK-Cu without a human outcome trial, systemic safety data, or supported repair protocol. | Copper binding and skin-remodeling biology do not define injectable exposure, tissue distribution, immune response, or long-term safety. | Gray-market and clinic discussion may describe injectable GHK-Cu for recovery, skin, hair, or broad anti-aging. Those claims are less supported than the topical evidence and do not set a clinical standard. | Injectable GHK-Cu lacks direct human support in the cited evidence. For injectable claims, FDA's safety-risk warning is a major part of the answer. |
| A copper-peptide cosmetic product is automatically low-risk because it is topical. | Topical exposure is not the same as injectable exposure, but topical products still need formulation, irritation, claim, and product-category review. The FDA cosmetic/drug distinction depends partly on intended use and claims. | GHK-Cu is hydrophilic and formulation-sensitive, so delivery system, concentration, excipients, and skin condition can change the product-quality issue. | Consumer products often use reassuring cosmetic language while making broad repair or regeneration claims. That makes the exact product and claim important. | Topical is the better-supported route here, but the exact product and claim still matter. |
Bottom line
Main takeaway
GHK-Cu is a copper peptide with limited topical skin and wound evidence. Serums, wound products, hair products, blends, and injectable vials using the name can mean very different things.
Route and product determine the relevant exposure. A topical wrinkle serum, an ulcer dressing, a post-laser product, a hair serum, and an injectable gray-market vial can expose skin or tissue in very different ways.
The evidence hierarchy includes copper-binding chemistry, dermal-delivery work, topical human skin and wound studies, the mixed post-laser study, FDA cosmetic guidance, and FDA injectable-risk language. Broader claims extend beyond that evidence.
Identity
What it is
GHK is glycyl-L-histidyl-L-lysine, a short tripeptide found in the human body. GHK-Cu is its copper complex, which is why it often appears under the cosmetic ingredient name copper tripeptide-1.
It is discussed because copper-peptide biology connects naturally to skin remodeling, dermal delivery, wound-healing research, and cosmetic aging claims.
The same name appears on very different products. The listed evidence fits topical skin use much better than injectable anti-aging, tendon repair, systemic recovery, or hair-growth claims.
How people talk about it online
Online GHK-Cu discussion is broader than the evidence. People talk about fine lines, skin texture, post-laser recovery, scar appearance, hair density, scalp support, wound repair, tendon or joint recovery, and injectable anti-aging stacks.
Skin-appearance, wound, hair, and injectable-repair claims come from different products, routes, formulations, and bodies of evidence.
Blend pages and clinic stacks can also pull GHK-Cu into GHK-Cu + KPV or KLOW-style products. Once it is blended, the other ingredients, ratio, stability, route, sterility, and direct evidence for the finished product all matter.
Use context
Routes, doses, and cycle patterns
GHK-Cu use patterns split by route and product. The most concrete schedule in the documented human material is topical twice-daily use for 8 weeks in a wrinkle study. Other topical wound and post-procedure studies are documented, but they do not give one reusable amount, frequency, or duration. Hair and injectable use are common discussion areas; they are separate product categories from a topical serum and need their own route, formulation, and product-quality checks.
Human studies and product labels
Topical nano-carrier wrinkle study
- Purpose
- Facial wrinkle appearance
- Context
- Randomized split-face topical cosmetic study
- Route
- Topical facial serum
- Amount
- Not reported as a simple milligram amount in the listed wrinkle source
- Frequency
- Twice daily
- Duration
- 8 weeks
The 8-week, twice-daily serum schedule is the clearest topical schedule here. It supports modest skin-appearance claims, not injectable, blend, or whole-body anti-aging claims.
Topical diabetic-ulcer treatment context
- Purpose
- Diabetic ulcer healing
- Context
- Topical human wound-healing study context
- Route
- Topical
- Amount
- The listed source does not give a clean comparison amount
- Frequency
- The listed source does not give a clean comparison frequency
- Duration
- The listed source does not give a clean comparison duration
This supports topical wound-care discussion for a specific clinical setting. It does not translate into general systemic repair or injection claims.
Post-CO2-laser resurfacing topical products
- Purpose
- Post-laser skin recovery and appearance
- Context
- Human topical post-procedure skin study
- Route
- Topical skin-care products
- Amount
- The listed source does not give a clean comparison amount
- Frequency
- The listed source does not give a clean comparison frequency
- Duration
- The listed source does not give a clean comparison duration
Objective improvements were not significant for several post-laser measures, while patient satisfaction was higher. That keeps post-procedure claims from overstating the study.
Dermal-delivery formulation work
- Purpose
- Skin delivery and formulation feasibility
- Context
- Preformulation / dermal-delivery study
- Route
- Dermal / topical formulation context
- Amount
- Formulation research; no clinical dose amount is established here
- Frequency
- Formulation research, not a use schedule
- Duration
- Formulation research, not a treatment course
Formulation affects exposure. Delivery system, concentration, vehicle, and skin condition determine whether evidence for one GHK-Cu product applies to another.
Real-world discussion
Injectable community protocols
- Purpose
- Skin quality, hair, and recovery discussion
- Context
- Clinics, forums, and vendor listings
- Route
- Subcutaneous injection
- Amount
- Typically around 1 to 2 mg per day
- Frequency
- Once daily in most descriptions
- Duration
- Usually 4 to 8 week or longer runs
Injectable GHK-Cu schedules are community convention; the stronger evidence for GHK-Cu is topical and cosmetic, not systemic. Reported as context, not a recommendation.
Topical and cosmetic use
- Purpose
- Skin and hair
- Context
- Cosmetic products and clinics
- Route
- Topical serums and creams
- Amount
- Cosmetic products commonly describe roughly 2 to 4 percent GHK-Cu concentration
- Frequency
- Once or twice daily application
- Duration
- Ongoing cosmetic use
Topical use is a normal cosmetic category with a very different risk profile from injection, and the two should not be conflated.
What varies
- Route: topical skin data are not injectable or systemic-use evidence.
- Formulation: vehicle, concentration, copper-complex integrity, and delivery system can change the meaning of a GHK-Cu claim.
- Goal: wrinkles, post-procedure recovery, wound care, hair, and systemic repair are different claims.
- Product type: a cosmetic, drug-like topical claim, compounded preparation, research vial, and blend product need separate evaluation.
Human data
Human evidence
The human evidence for GHK-Cu is limited, with the clearest support for topical skin and wound contexts, including a topical wrinkle study, diabetic ulcer treatment context, and post-laser resurfacing evidence that includes mixed objective findings. These human sources cover topical skin and wound contexts, not injectable, systemic, hair-growth, tendon-repair, or blend claims.
Evidence maturity
GHK-Cu's evidence splits cleanly by route: a modest human cosmetic literature on top, unverified injectable claims underneath.
Plasma tripeptide-copper complex identified in the 1970s-80s, declining with age.
Small cosmetic and wound-adjacent human studies of creams and serums.
No comparable human evidence for systemic injectable use.
Legitimate cosmetic ingredient alongside gray-market injectable vials.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Topical GHK-Cu nano-carrier wrinkle study | Women in a split-face cosmetic wrinkle study | Randomized split-face topical study | Topical GHK-Cu nano-carrier serum | Reported reductions in wrinkle volume and depth after twice-daily topical use for 8 weeks. | Short cosmetic study, topical formulation, and no support for injectable, systemic, or blend claims. | Limited human topical evidence |
| Topical diabetic-ulcer study context | Patients with diabetic ulcers | Human topical wound-healing study context | Topical GHK-Cu treatment context | Supports discussion of topical GHK-Cu in a specific wound-care setting. | Older study context, indication-specific use, and no transfer to injectable or systemic wellness claims. | Limited to moderate human topical wound context |
| Post-CO2-laser resurfacing topical study | People with CO2 laser-resurfaced skin | Human topical post-procedure skin study | Topical copper tripeptide complex skin-care products | Several objective post-laser measures failed to improve significantly, while patient satisfaction was higher. | Mixed findings and a procedure-specific setting keep the result from supporting broad skin regeneration or injectable use. | Limited and mixed human topical evidence |
| Dermal-delivery preformulation work | Laboratory and formulation context | Preformulation and dermal-delivery study | Topical / dermal formulation development | Supports the idea that vehicle and delivery design matter for GHK-Cu skin use. | Formulation work explains delivery, not a clinical outcome, dose, or universal product standard. | Mechanistic / formulation support |
Cautions
Safety and unknowns
- Topical and injectable safety are separate questions. Cosmetic tolerability does not answer systemic safety, sterile injection safety, or long-term repeated-exposure questions.
- Skin irritation, allergy-like reactions, barrier disruption, post-procedure skin sensitivity, and excipient reactions matter for topical products.
- Copper exposure is part of the identity of GHK-Cu. Product concentration, copper-complex integrity, and repeated-use context vary across products.
- Injectable products raise separate concerns: identity, aggregation, peptide-related impurities, immunogenicity, sterility, endotoxin, concentration error, and route-specific safety.
- Hair, tendon, systemic recovery, and anti-aging uses have far less direct support in the standalone GHK-Cu evidence summarized here than topical skin uses.
Product quality
A vial label is only a starting point
A GHK-Cu product needs to be judged by route and formulation, not just by the ingredient name.
For topical products, vehicle, concentration, copper-complex integrity, pH, preservatives, packaging, skin condition, and claim wording all matter.
For injection-centered products, a purity number or informal test does not answer sterility, endotoxin, aggregation, concentration, label accuracy, or immune-response questions.
For blends, product evidence would need to verify each active ingredient, each amount, compatibility, stability after mixing, and whether the combined product matches any studied context.
Color check for topical products
The copper-peptide complex is blue. A topical GHK-Cu product with no blue tint has lost the copper from the complex, so the active complex is no longer what the label describes.
Identity
A product record should identify the copper complex, not just a vague copper peptide or a generic skin-care ingredient.
Formulation
Dermal delivery is formulation-sensitive, so a serum, cream, gel, dressing, injectable vial, and blend cannot be judged as the same product.
Route-specific quality
Topical products and injectable products have different contamination, sterility, endotoxin, concentration, and immune-response questions.
Claims
Cosmetic appearance wording, wound-treatment wording, hair-growth wording, and disease-treatment wording can change both the evidence needed and the regulatory category.
Mechanism
How it is proposed to work
GHK-Cu is studied because GHK binds copper, and copper is involved in many skin and tissue processes. In plain terms, the molecule is discussed as a small copper-binding molecule tied to skin remodeling, dermal delivery, and wound-repair biology.
Copper-binding work shows the basic chemistry: GHK interacts with copper(II), which helps explain why the complex is discussed as more than an ordinary cosmetic buzzword.
Dermal-delivery work matters because GHK-Cu is not skin-penetrating in every product. Vehicle and formulation can change how much reaches the relevant skin layers.
Skin-remodeling claims are strongest when they stay close to topical human studies and formulation work. They do not, by themselves, justify systemic recovery, injectable anti-aging, tendon repair, or blend claims.
GHK is a plasma tripeptide (Gly-His-Lys) with high affinity for copper ions, and its plasma level falls substantially with age in the published measurements. Proposed actions include modulation of TGF-beta family signaling, matrix metalloproteinase balance, and antioxidant effects.
The cosmetic evidence constraint is physical as much as biological: skin penetration of a hydrophilic copper-peptide complex is limited, which is why formulation (liposomes, delivery systems) dominates the serious topical literature.
FAQ
Common questions
Does GHK-Cu work for skin?
The topical evidence is the strongest part of the story: small human cosmetic and wound-adjacent studies support skin-quality claims for creams and serums. The injectable systemic claims popular online have no comparable human backing.
What is the difference between topical and injectable GHK-Cu?
Topical GHK-Cu is a normal cosmetic ingredient with a modest human literature. Injectable use — commonly 1 to 2 mg daily in community protocols — is a separate, unverified practice, and evidence from one format does not transfer to the other.
Is GHK-Cu a copper supplement?
No. It is a tripeptide that binds copper ions, originally isolated from human plasma. Supplementing copper and administering the peptide-copper complex are different things with different evidence.
Details
Technical details
Sources
References
- 1.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 2.
PubMed. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper 1994.
PMID:17147644 Accessed 2026-06-08.
Topical diabetic-ulcer source; not evidence for injectable or systemic claims.
- 3.
PubMed. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin 2006.
PMID:16847171 Accessed 2026-06-08.
Topical post-laser skin source; formulation and indication matter.
- 4.
PMID:25384620 Accessed 2026-06-08.
Dermal-delivery formulation context; not systemic efficacy evidence.
- 5.
PubMed. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma 1981.
PMID:7340824 Accessed 2026-06-08.
Copper-binding chemistry source for mechanism context.
- 6.
FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) 2026.
Accessed 2026-06-08.
FDA consumer product boundary source; product claims can change regulatory posture.
- 7.
Other. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production and Facial Wrinkle Parameters 2016.
Accessed 2026-06-14.
Randomized split-face topical GHK-Cu nano-carrier wrinkle study in women; relevant to topical GHK-Cu, not blend or injectable claims.